NFE2L2 and lung carcinoma: This is also reflected by the fact that in the clinical setting, upregulation of NRF2 is associated with poor prognosis and decreased overall survival in patients with lung cancer [277], head and neck cancer [254], oesophageal cancer [233], gastric cancer [278], liver cancer [279] and colorectal cancer [267,269].